Outcomes included change from baseline at week 40 in HbA1c (primary outcome) and bodyweight (secondary confirmatory outcome), evaluated through trial product estimand (no treatment discontinuation or without rescue medication) and treatment policy estimand (regardless of treatment discontinuation or rescue medication) strategies
The label describes the product as non-GMO, stimulant-free, and free from common allergens including milk, egg, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame
Novo Nordisk Press Release: Advances early-stage obesity medication, amycretin, to Phase 3 clinical development
Finding: Semaglutide reduced the risk of major kidney events by 24% and major cardiovascular events by 18%
Though launched five years after Semaglutide (in 2022), it achieved $3.84 billion in Q1 sales
Who qualifies for GLP-1 coverage under the new plan